LT2257307T - Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių - Google Patents

Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių

Info

Publication number
LT2257307T
LT2257307T LTEP09712440.8T LT09712440T LT2257307T LT 2257307 T LT2257307 T LT 2257307T LT 09712440 T LT09712440 T LT 09712440T LT 2257307 T LT2257307 T LT 2257307T
Authority
LT
Lithuania
Prior art keywords
recombinant
glycosylated proteins
procaryotic cells
bioconjugates
bioconjugates made
Prior art date
Application number
LTEP09712440.8T
Other languages
English (en)
Inventor
Fabiana Fernandez
Michael Wetter
Michael Kowarik
Michael Wacker
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of LT2257307T publication Critical patent/LT2257307T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
LTEP09712440.8T 2008-02-20 2009-02-19 Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių LT2257307T (lt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US6416308P 2008-02-20 2008-02-20
US7154508P 2008-05-05 2008-05-05
US12948008P 2008-06-30 2008-06-30
US12985208P 2008-07-24 2008-07-24
US13668708P 2008-09-25 2008-09-25
PCT/IB2009/000287 WO2009104074A2 (en) 2008-02-20 2009-02-19 Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells

Publications (1)

Publication Number Publication Date
LT2257307T true LT2257307T (lt) 2018-08-10

Family

ID=40888413

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP09712440.8T LT2257307T (lt) 2008-02-20 2009-02-19 Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių

Country Status (19)

Country Link
US (4) US8895014B2 (lt)
EP (2) EP3427749A1 (lt)
JP (2) JP5782258B2 (lt)
KR (1) KR20100123730A (lt)
CN (1) CN101983070B (lt)
AU (1) AU2009215341B2 (lt)
CA (1) CA2716187C (lt)
CY (1) CY1120512T1 (lt)
DK (1) DK2257307T3 (lt)
ES (1) ES2684129T3 (lt)
HR (1) HRP20181259T1 (lt)
HU (1) HUE039413T2 (lt)
IL (1) IL207350A (lt)
LT (1) LT2257307T (lt)
PL (1) PL2257307T3 (lt)
PT (1) PT2257307T (lt)
SG (1) SG10201400320TA (lt)
SI (1) SI2257307T1 (lt)
WO (1) WO2009104074A2 (lt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8092788B2 (en) 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US10105448B2 (en) 2005-01-11 2018-10-23 The United States Of America As Represented By The Secretary Of The Navy Combined enteropathogen recombinant construct
ZA200707352B (en) * 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
LT2257307T (lt) * 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
CN102724997B (zh) * 2009-11-19 2016-09-21 格林考瓦因有限公司 在原核细胞中产生免疫原性多糖的生物合成系统
EP2545081B1 (en) 2010-02-11 2015-01-28 The Governors of the University of Alberta N-Linked Glycan Compounds
JP6339366B2 (ja) * 2010-05-06 2018-06-06 グリコヴァキシン アーゲー 莢膜グラム陽性菌のバイオコンジュゲートワクチン
WO2012027850A1 (en) * 2010-09-03 2012-03-08 Christine Szymanski Peptide containing multiple n-linked glycosylation sequons
KR20120062457A (ko) 2010-12-06 2012-06-14 삼성전자주식회사 솔더 접합 신뢰도를 높이는 반도체 패키지용 인쇄회로기판 및 이를 포함하는 반도체 패키지
US20150316549A2 (en) 2011-08-12 2015-11-05 Mario Feldman Method of diagnosing bacterial infections using bacterial glycoproteins
CA2847621A1 (en) 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
WO2013159234A1 (en) 2012-04-27 2013-10-31 The Governors Of The University Of Alberta Glycoengineered outer membrane vesicles and use thereof as vaccines
EP2877205A4 (en) 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
BR112015004817A2 (pt) * 2012-09-10 2017-07-04 Glycovaxyn Ag bioconjugados compreendendo antígenos modificados e seus usos
ES2720040T3 (es) * 2012-10-12 2019-07-17 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
EP2724730A1 (en) 2012-10-29 2014-04-30 Institut Pasteur Glycoconjugates and their use as potential vaccines against infection by Shigella Flexneri
US20150273043A1 (en) 2012-11-07 2015-10-01 Glycovaxyn Ag Production of recombinant vaccine in e.coli by enzymatic conjugation
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
CA2923957C (en) 2013-01-18 2021-08-31 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
CA2926523C (en) * 2013-10-11 2023-09-26 Glycovaxyn Ag Methods of host cell modification
JP6276427B2 (ja) * 2014-02-24 2018-02-07 グリコヴァキシン アーゲー 新規の多糖及びその使用
HUE049806T2 (hu) 2014-04-17 2020-10-28 Glaxosmithkline Biologicals Sa Módosított gazdasejtek és alkalmazásaik
EP4183408A1 (en) * 2014-09-24 2023-05-24 The United States of America as Represented by The Secretary of the Navy Combined enterotoxigenic escherichia coli and shigella recombinant
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
AU2015342943B2 (en) 2014-11-05 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
CN105734001B (zh) * 2014-12-08 2020-04-07 中国人民解放军军事医学科学院生物工程研究所 一种o抗原糖链延长的甲型副伤寒沙门氏菌及其应用
DK3240895T3 (da) * 2014-12-30 2022-04-11 Glaxosmithkline Biologicals Sa Sammensætninger og fremgangsmåder til proteinglykosylering
EP3050973A1 (en) * 2015-01-30 2016-08-03 Jennewein Biotechnologie GmbH Fermentation process for producing monosaccharides in free form from nucleotide-activated sugars
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017175239A1 (en) 2016-04-05 2017-10-12 Council Of Scientific & Industrial Research A multifunctional recombinant nucleotide dependent glycosyltransferase protein and its method of glycosylation thereof
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
GB201615427D0 (en) 2016-09-12 2016-10-26 London School Of Hygeine & Tropical Medicine Francisella glycoconjugate vaccines
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN106801029B (zh) * 2017-01-22 2020-05-01 山东大学 一株重组大肠杆菌及其在制备抗志贺氏菌的糖疫苗中的应用
GB201704117D0 (en) 2017-03-15 2017-04-26 London School Hygiene & Tropical Medicine Oligosaccharyl Transferase polypeptide
CA3054765A1 (en) * 2017-03-15 2018-09-20 London School Of Hygiene And Tropical Medicine Whole cell vaccines
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US11530432B2 (en) * 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
EA202192392A1 (ru) 2019-03-18 2022-02-09 Янссен Фармасьютикалз, Инк. Способы получения биоконъюгатов полисахаридных о-антигенов e.coli, их композиции и способы их применения
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
PL4010467T3 (pl) 2019-08-09 2024-08-05 Glaxosmithkline Biologicals Sa Zmutowane enzymy oligosacharylotransferazy pglb
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、その組成物、及びその使用
EP4168040A1 (en) 2020-06-18 2023-04-26 GlaxoSmithKline Biologicals S.A. Shigella-tetravalent (shigella4v) bioconjugate
CN115996749A (zh) 2020-06-25 2023-04-21 葛兰素史克生物有限公司 经修饰的外毒素a蛋白
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
PL4252003T3 (pl) * 2020-11-30 2025-08-04 Janssen Pharmaceuticals, Inc. Sposób analityczny dla glikokoniugatów z zastosowaniem systemu oznaczania immunologicznego na bazie kapilar
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
EP4281108A1 (en) 2021-04-08 2023-11-29 Janssen Pharmaceuticals, Inc. Process for bioconjugate production
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4478050A1 (en) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Method for quantifying bound acetate in glycoconjugates
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
EP0646175B1 (en) * 1992-06-18 2005-12-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant pseudomonas exotoxin with increased activity
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3508300A (en) 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
EP1285072A2 (en) 2000-05-12 2003-02-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
WO2002000856A2 (en) 2000-06-30 2002-01-03 Flanders Interuniversity Institute For Biotechnology (Vib) Protein glycosylation modification in pichia pastoris
KR20100119905A (ko) 2002-03-07 2010-11-11 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
US7598354B2 (en) 2002-08-01 2009-10-06 National Research Council Of Canada Campylobacter glycans and glycopeptides
ATE550437T1 (de) * 2003-08-01 2012-04-15 Us Gov Health & Human Serv Verfahren zur expression und reinigung von immunotoxinen
EP1756149B1 (en) * 2004-05-24 2013-09-04 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Live, oral vaccine for protection against shigella dysenteriae serotype 1
DK1888761T3 (da) * 2005-05-11 2010-11-01 Eth Zuerich Rekombinante N-glycosylerede proteiner fra prokaryote celler
LT2257307T (lt) 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
JP6339366B2 (ja) 2010-05-06 2018-06-06 グリコヴァキシン アーゲー 莢膜グラム陽性菌のバイオコンジュゲートワクチン

Also Published As

Publication number Publication date
US10835592B2 (en) 2020-11-17
US20150044254A1 (en) 2015-02-12
EP2257307B1 (en) 2018-06-06
CY1120512T1 (el) 2019-07-10
EP3427749A1 (en) 2019-01-16
EP2257307A2 (en) 2010-12-08
US20210085772A1 (en) 2021-03-25
CN101983070A (zh) 2011-03-02
AU2009215341B2 (en) 2015-03-26
JP5782258B2 (ja) 2015-09-24
AU2009215341A1 (en) 2009-08-27
DK2257307T3 (en) 2018-08-20
WO2009104074A2 (en) 2009-08-27
IL207350A (en) 2017-10-31
PL2257307T3 (pl) 2018-11-30
CA2716187A1 (en) 2009-08-27
US11944675B2 (en) 2024-04-02
US20240277824A1 (en) 2024-08-22
SG10201400320TA (en) 2014-05-29
PT2257307T (pt) 2018-10-22
KR20100123730A (ko) 2010-11-24
US8895014B2 (en) 2014-11-25
ES2684129T3 (es) 2018-10-01
CA2716187C (en) 2020-01-07
US20110097357A1 (en) 2011-04-28
WO2009104074A3 (en) 2009-11-05
HUE039413T2 (hu) 2018-12-28
JP2011514155A (ja) 2011-05-06
SI2257307T1 (sl) 2018-09-28
IL207350A0 (en) 2010-12-30
JP6122071B2 (ja) 2017-04-26
JP2015187174A (ja) 2015-10-29
CN101983070B (zh) 2016-03-30
HK1155938A1 (zh) 2012-06-01
HRP20181259T1 (hr) 2018-10-05

Similar Documents

Publication Publication Date Title
IL207350A0 (en) Bioconjugates made from recombinant n - glycosylated proteins from procaryotic cells
SG10201608059VA (en) Recombinant vwf formulations
HRP20130414T1 (en) Lyophilized recombinant vwf formulations
IL202213A0 (en) Recombinant protein production in avian ebxr cells
ZA201101166B (en) Modified bovine g-csf polypeptides and their uses
ZA201109364B (en) Stabilized protein compositions
SG10201608071YA (en) Biologically active peptides
IL211670A0 (en) Therapeutic protein formulations
IL267556A (en) A pharmaceutical preparation containing recombinant hcg
GB0921241D0 (en) Protein formulation
ZA201104670B (en) Pharmaceutical composition comprising aleglitazar
EP2102231A4 (en) IMPROVED EXPRESSION SYSTEM FOR RECOMBINANT HUMAN ARGINASE I
ZA201105784B (en) Recombinant porcine chymotrypsin
EP2254901A4 (en) THERAPEUTIC PEPTIDES
EP2314701A4 (en) RECOMBINANT EXPRESSION VECTOR FOR ANIMAL CELL
GB2462726B (en) Protein expression
GB0807929D0 (en) Protein formulation
GB0803594D0 (en) Protein formulation
GB0811893D0 (en) Protein expression
GB0810567D0 (en) Protein expression